Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

Trial Details

NCT ID
NCT03484299
Phase
PHASE1
Sponsor
University of Louisville
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Irreversible Electroporation (IRE)
  • Gemcitabine
  • FOLFIRINOX
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • greater than or equal to 18 years of age
  • diagnosed with stage III pancreatic cancer
  • tumor is measurable
  • GFR \> mL/min/1.73m2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →